Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 300 Carcinoma, Non-Small-Cell Lung 262 Neoplasms 242 Prostatic Neoplasms 204 Colorectal Neoplasms 187 Lung Neoplasms 145 Multiple Myeloma 141 Neoplasm Metastasis 126 Ovarian Neoplasms 123 Leukemia, Myeloid, Acute 115 Pancreatic Neoplasms 109 Melanoma 96 Squamous Cell Carcinoma of Head and Neck 93 Recurrence 80 Endometrial Neoplasms 78 Carcinoma, Renal Cell 76 Lymphoma, Non-Hodgkin 74 Lymphoma 70 Stomach Neoplasms 69 Precursor Cell Lymphoblastic Leukemia-Lymphoma 69 Carcinoma, Hepatocellular 67 Glioblastoma 66 Brain Neoplasms 64 Sarcoma 62 Glioma 62 Uterine Cervical Neoplasms 59 Head and Neck Neoplasms 59 Triple Negative Breast Neoplasms 57 Leukemia, Lymphocytic, Chronic, B-Cell 54 Urinary Bladder Neoplasms 51

Interventions

relatlimab 1 pembrolizumab 1 lifileucel 1 Temozolomide 1 Paclitaxel 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Dacarbazine 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Melanoma, Cutaneous Malignant × 30 days × Clear all

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡